Zhou, Yu-Peng
Wilks, Moses Q.
Dhaynaut, Maeva
Guehl, Nicolas J.
Vesper, Danielle R.
Moon, Sung-Hyun
Rice, Peter A.
El Fakhri, Georges
Normandin, Marc D.
Brugarolas, Pedro http://orcid.org/0000-0002-7455-2743
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01NS114066)
National Institute of Biomedical Imaging and Bioengineering (K99EB033407, P41EB022544)
NIH Office of the Director (S10OD018065)
Article History
Received: 19 December 2023
Accepted: 4 March 2024
First Online: 29 April 2024
Declarations
:
: All experiments involving non-human primates were performed in accordance with the U.S. Department of Agriculture (USDA) Animal Welfare Act and Animal Welfare Regulations (Animal Care Blue Book), Code of Federal Regulations (CFR), Title 9, Chapter 1, Subchapter A, Part 2, Subpart C, §2.31. 2017. Animal experiments were approved by the Animal Care and Use Committee (IACUC) at the Massachusetts General Hospital (MGH).
: Not applicable.
: PB has a financial interest in Fuzionaire Theranostics (p/k/a Fuzionaire Diagnostics) and the University of Chicago. PB is a named inventor of patents related to [<sup>18</sup>F]3F4AP owned by the University of Chicago and licensed to Fuzionaire. PB’s interests were reviewed and are managed by the MGH and Mass General Brigham in accordance with their conflict of interest policies. The other authors declare no competing interests.